Liberator Medical Holdings (LBMH) Merger Review

Liberator Medical Holdings (LBMH) announced it has entered into a definitive agreement with C.R. Bard for $3.35 in cash per share.


Liberator Medical Holdings shareholders are entitled to answers to important questions regarding the proposed merger

Does the merger agreement contain unfair termination provisions? At least one analyst set a price target of $8.00 per Liberator Medical share.
Does the merger agreement place perhaps an undue burden on the board of directors relating to subsequent offers from third parties?
Did the Liberator Medical’s board of directors obtain a fairness opinion from an independent investment bank?
What did the independent fairness show?
Did the board of directors engage other potential suitors?


Liberator Medical Holdings’s merger or takeover shareholder lawsuit investigation

State security laws provide shareholders a no cost means to question a proposed sale of a publicly traded company.  This review process is deemed a shareholder class action and affords at times shareholders an avenue to investigate fully the proposed transaction.  At minimum, this process often obtains answers to the above questions.  If you own the common stock of Liberator Medical Holdings and if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the contact form on this web page.







Article Type: Investigation
Topic: Investments
No case events.
Tags: Corporate Merger Reviews